🔗 Share this article

As the US continues making sweeping revisions to its vaccine recommendations, a particular individual has surfaced in a surprising turn: Høeg, a US-based sports medicine doctor and public health researcher who rose to prominence by expressing skepticism about Covid shots throughout the pandemic and has concentrated on alleged deaths after Covid immunization in her recent position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials had intended to announce radical revisions to the childhood vaccine schedule earlier this month, bringing the US with Denmark’s immunization schedule, sources say – a major change that would put the US out of alignment with many the world with no evidence for benefit. The announcement has been delayed until the new year.

Rather than the director of the vaccine center, Tracy Beth Høeg is scheduled to present at the meeting. She was recently named interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the office this calendar year.

Consolidating Power at the Regulatory Body

Høeg's temporary position might represent a tighter collaboration between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it points to a greater focus upon reevaluating long-standing immunizations at the FDA.

Dr. Høeg has often pushed for ending specific childhood shot schedules in the US so as to align more like Denmark's approach, a nation with nationalized medicine and a citizenry approximately the population of Wisconsin’s.

So far comments, she has persisted in emphasizing on immunizations – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Expertise

Høeg has no obvious experience in pharmaceutical research, regulation or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the FDA chief and CBER since March.

“She doesn’t seem to have the requisite experience” for leading the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in leading a large organization. She lacks background in drug approvals.”

Former directors of CBER would “be deeply familiar with laws and regulations and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Clearly, she has not acquired the kind of background that prior appointees who headed the center have had.”

The drug center has an immense range of responsibilities at the agency, Woodcock emphasized.

“Many people just pays attention on the novel medication approvals, but the generic program approves thousands of off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and more, and each of these must be managed,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is the part that I always told people is going to come back to haunt you.”

There is also, a significant leadership element to the position, which supervises over 5,000 staff members. “It’s a enormous leadership role, if you do it right,” she said.

Response and Disputed Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary responded that the “questions are based on flawed presumptions”.

“This background aligns with the functions of her job,” the representative said, pointing to the period Dr. Høeg spent advising the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the commissioner’s new priority voucher program, a disputed expedited drug-approval program that apparently worried her former heads. “By what process are these medications being picked for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality happening at the agency right now.”

In general, he said, “the FDA looks to be trending towards laxer rules of all drugs, aside from immunizations.”

Documented History on Vaccines

With immunizations, Høeg has a more established, if troubling, past, Howard observe. She authored a study using non-validated public submissions to assess the incidence of heart inflammation following Covid vaccination. She consulted for the state of Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the incoming federal leadership encompassed changing rules for novel immunizations and halting “optional” immunizations, she stated post-election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding adolescent males from obtaining COVID-19 vaccines.

“She is an complete true believer who begins with her conclusions and works backwards to fit the science in a extremely deceptive, dishonest fashion,” Howard argued.

Taking Control and a “Push for Payback”

Høeg joined fellow contrarians, {like|